Compare EU & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EU | PCRX |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 501.9M | 1.0B |
| IPO Year | N/A | 2011 |
| Metric | EU | PCRX |
|---|---|---|
| Price | $2.51 | $25.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $4.00 | ★ $32.86 |
| AVG Volume (30 Days) | ★ 2.8M | 870.0K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | $44,142,000.00 | ★ $716,791,000.00 |
| Revenue This Year | $17.41 | $6.24 |
| Revenue Next Year | $95.45 | $9.53 |
| P/E Ratio | ★ N/A | $55.21 |
| Revenue Growth | N/A | ★ 3.14 |
| 52 Week Low | $1.01 | $18.17 |
| 52 Week High | $4.19 | $27.64 |
| Indicator | EU | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.85 | 60.19 |
| Support Level | $2.28 | $25.48 |
| Resistance Level | $2.78 | $27.16 |
| Average True Range (ATR) | 0.18 | 1.02 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 27.67 | 67.69 |
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.